(Q22241777)

inferred from title

author

Robert Vander Stichele

1 reference

ORCID Public Data File 2021

F. Matthys

1

Frederik

Matthys

1 reference

PubMed

7 February 2023

T. De Backer

series ordinal

2

author given names

Tine

author last names

De Backer

1 reference

PubMed

7 February 2023

G. De Backer

series ordinal

3

author given names

Guy

author last names

De Backer

1 reference

PubMed

European Journal of Preventive Cardiology

7 February 2023

R. V. Stichele

series ordinal

4

0 references

language of work or name

English

0 references

publication date

20 December 2012

0 references

published in

0 references

volume

21

0 references

issue

3

0 references

page(s)

354-365

0 references

cites work

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

1 reference

https://api.crossref.org/works/10.1177/2047487312472077

Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System

20 April 2017

1 reference

https://api.crossref.org/works/10.1177/2047487312472077

Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials

20 April 2017

1 reference

https://api.crossref.org/works/10.1177/2047487312472077

An Update on Aspirin in the Primary Prevention of Cardiovascular Disease

20 April 2017

1 reference

https://api.crossref.org/works/10.1177/2047487312472077

Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force

20 April 2017

1 reference

https://api.crossref.org/works/10.1177/2047487312472077

A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women

20 April 2017

1 reference

https://api.crossref.org/works/10.1177/2047487312472077

Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial

20 April 2017

1 reference

https://api.crossref.org/works/10.1177/2047487312472077

Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials

20 April 2017

1 reference

https://api.crossref.org/works/10.1177/2047487312472077

Aspirin for everyone older than 50? Against

20 April 2017

1 reference

https://api.crossref.org/works/10.1177/2047487312472077

Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies

20 April 2017

1 reference

https://api.crossref.org/works/10.1177/2047487312472077

Aspirin for the Primary Prevention of Cardiovascular Events: An Update of the Evidence for the U.S. Preventive Services Task Force

20 April 2017

1 reference

https://api.crossref.org/works/10.1177/2047487312472077

Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications

20 April 2017

1 reference

https://api.crossref.org/works/10.1177/2047487312472077

Prediction of Coronary Heart Disease Using Risk Factor Categories

20 April 2017

1 reference

https://api.crossref.org/works/10.1177/2047487312472077

Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

20 April 2017

1 reference

https://api.crossref.org/works/10.1177/2047487312472077

Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A Scientific Statement From the American Heart Association and the American Diabetes Association

20 April 2017

1 reference

https://api.crossref.org/works/10.1177/2047487312472077

Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use

20 April 2017

1 reference

https://api.crossref.org/works/10.1177/2047487312472077

Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control

20 April 2017

1 reference

https://api.crossref.org/works/10.1177/2047487312472077

Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis

20 April 2017

1 reference

https://api.crossref.org/works/10.1177/2047487312472077

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

20 April 2017

1 reference

https://api.crossref.org/works/10.1177/2047487312472077

Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events

20 April 2017

1 reference

https://api.crossref.org/works/10.1177/2047487312472077

Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan

20 April 2017

1 reference

https://api.crossref.org/works/10.1177/2047487312472077

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men

20 April 2017

1 reference

https://api.crossref.org/works/10.1177%2F2047487312472077

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted

20 April 2017

1 reference

https://api.crossref.org/works/10.1177%2F2047487312472077

Extending the GEM model to support knowledge extraction from textual guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487312472077

Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487312472077

Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487312472077

Aspirin in primary prevention: sex and baseline risk matter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487312472077

Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487312472077

Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487312472077

The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487312472077

Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487312472077

Aspirin for primary prevention of cardiovascular events in people with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487312472077

Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487312472077

Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487312472077

Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487312472077

Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487312472077

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487312472077

Final report on the aspirin component of the ongoing Physicians' Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487312472077

Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487312472077

Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487312472077

AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487312472077

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487312472077

Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487312472077

Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487312472077

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487312472077

Incidence of serious upper gastrointestinal bleeding/perforation in the general population: review of epidemiologic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487312472077

Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487312472077

Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487312472077

Diabetes, microvascular complications, and cardiovascular complications: what is it about glucose?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487312472077

Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487312472077

Aspirin as an antiplatelet drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487312472077

Platelet activation and atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487312472077

Aspirin resistance transient laboratory finding or important clinical entity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487312472077

Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance".

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487312472077

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487312472077

Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487312472077

Association of aspirin use with major bleeding in patients with and without diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487312472077

Comparisons of established risk prediction models for cardiovascular disease: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487312472077

Differences among international pharyngitis guidelines: not just academic

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487312472077

Probability of stroke: a risk profile from the Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487312472077

Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487312472077

7 January 2021

Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators

1 reference

https://api.crossref.org/works/10.1177%2F2047487312472077

7 January 2021

1 reference

https://api.crossref.org/works/10.1177%2F2047487312472077

7 January 2021

Baseline Characteristics of Participants in the Women's Health Study

1 reference

https://api.crossref.org/works/10.1177%2F2047487312472077

7 January 2021

Prevention of cardiovascular disease in type-2 diabetes: how to improve the clinical efficacy of aspirin

1 reference

https://api.crossref.org/works/10.1177%2F2047487312472077

7 January 2021

Unstable angina. A comparison of angioscopic findings between diabetic and nondiabetic patients

1 reference

https://api.crossref.org/works/10.1177%2F2047487312472077

7 January 2021

Compliance with cardiovascular drug prevention measures in a general population: the Multidisciplinary Intervention in Primary Care (IMAP) study

1 reference

https://api.crossref.org/works/10.1177%2F2047487312472077

7 January 2021

Identifiers

DOI

10.1177/2047487312472077

0 references